Latham & Watkins LLP represented SQZ Biotechnologies Company in the transaction. SQZ Biotechnologies Company (NYSE: SQZ) (SQZ), a cell therapy company developing novel treatments for multiple...
SQZ Biotechnologies’ $60 Million Common Stock Offering
Nano-X Imaging’s Secondary Public Offering
Latham & Watkins LLP represented the underwriters in the offering. NANO-X IMAGING LTD (NASDAQ: NNOX), an innovative medical imaging technology company, has announced that it has...


























